Chase William J's Form 4 filing
Intellia Therapeutics, Inc.NTLA · filed Aug 22, 2025
- Accession no.
- 0000950170-25-110979
- Filed
- Aug 22, 2025
- Trade date
- Aug 20, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $1.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Chase William JCIK 0001563572 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 20, 2025 | Common Stock | PPurchaseAcquired | +100,000 | $10.03F2 | +$1,003,000 | 134,693 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.97 to $10.04, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on August 20, 2025 at each separate price.
Referenced by the price of 1 transaction in Table I.